Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM674MP)

Drug Name

CLT030 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Myeloid inhibitory C-type lectin-like receptor (CD371)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CD123/CLL1 CAR-T Cells	DM45Z3P	Acute myeloid leukaemia	2A60	Phase 2/3	[3]
CLL1 CAR-T Cell	DMUOMBZ	Acute myeloid leukaemia	2A60	Phase 2/3	[3]
CLL1-specific gene-engineered T cells	DMCT917	Acute myeloid leukaemia	2A60	Phase 1/2	[4]
CAR-T cells targeting CLL1	DMCPM92	leukaemia	2A60-2B33	Phase 1/2	[5]
Tepoditamab	DMC84Y9	Acute myelogenous leukaemia	2A41	Phase 1	[6]
CLL1-CD33 cCART cell therapy	DM5EM04	Acute myeloid leukaemia	2A60	Phase 1	[7]
KITE-222	DMPF49Z	Acute myeloid leukaemia	2A60	Phase 1	[8]
UCART-CLL1	DMT06MI	Multiple myeloma	2A83	Preclinical	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Myeloid inhibitory C-type lectin-like receptor (CD371)	TT70N8V	CL12A_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia. Blood Adv. 2018 Jul 24;2(14):1738-1749.
2	Clinical pipeline report, company report or official report of Cellerant Therapeutics.
3	ClinicalTrials.gov (NCT03631576) CD123/CLL1 CAR-T Cells for R/R AML
4	ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
5	ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
6	MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis. Expert Opin Biol Ther. 2019 Jul;19(7):721-733.
7	Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
8	Clinical pipeline report, company report or official report of Gilead
9	Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020 Mar;19(3):185-199.